Pliant Therapeutics, Inc.
Clinical trials sponsored by Pliant Therapeutics, Inc., explained in plain language.
-
Can a new pill slow lung scarring? small trial holds promise for IPF patients
Disease control CompletedThis study tested an experimental drug called PLN-74809 in 10 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. Participants took the drug or a placebo daily for 12 weeks. The main goal was to see if the drug could reduce collagen b…
Phase: PHASE2 • Sponsor: Pliant Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 12:05 UTC
-
New drug shows promise for rare liver disease in early trial
Disease control CompletedThis study tested an experimental drug called PLN-74809 in 121 adults with primary sclerosing cholangitis (PSC) and suspected liver scarring. The main goal was to check the drug's safety and how the body processes it. Participants received different doses of the drug or a placebo…
Phase: PHASE2 • Sponsor: Pliant Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC